海南海药：关于子公司注射用美罗培南通过仿制药质量和疗效一致性评价的公告

Core Points - Hainan Haiyao announced that its wholly-owned subsidiary, Haikou Pharmaceutical Factory, has received approval from the National Medical Products Administration for the supplementary application of injectable Meropenem [2] - The approval confirms that the product has passed the consistency evaluation of quality and efficacy for generic drugs [2] Company Summary - Hainan Haiyao's subsidiary has successfully obtained a significant regulatory approval, which may enhance its product portfolio and market competitiveness [2] - The approval of injectable Meropenem indicates the company's commitment to maintaining high standards in drug quality and efficacy [2] Industry Summary - The approval reflects the ongoing efforts within the pharmaceutical industry to ensure that generic drugs meet stringent quality and efficacy standards [2] - This development may signal a positive trend for other companies in the industry seeking similar approvals for their products [2]